Alyeska Investment Group
TXMD icon

Alyeska Investment Group’s TherapeuticsMD TXMD Stock Holding History

Alyeska Investment Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,620
Closed -$1.4M – 515
2017
Q4 		$1.4M Sell
4,620
-6,012
-57% -$1.67M 0.01% 364
2017
Q3 		$2.81M Buy
+10,632
New +$3.07M 0.02% 330

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group's TXMD Position: Q1 2018 in Review

Alyeska Investment Group sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 4,620 shares — an estimated $1.4M sold.

Alyeska Investment Group first reported a position in TXMD in Q3 2017 and held it in 2 quarters. The position peaked at $2.81M in Q3 2017. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

  • Alyeska Investment Group reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 4,620 TherapeuticsMD shares in Q1 2018, an estimated $1.4M.
  • Alyeska Investment Group first reported a position in TherapeuticsMD in Q3 2017 and held it in 2 quarters.
  • Alyeska Investment Group's TherapeuticsMD position peaked at $2.81M in Q3 2017.
  • 143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Alyeska Investment Group's 13F filing for Q1 2018, filed 15 May 2018.